Search
Epoetin delta
go.drugbank.com/drugs/DB11624ApprovedWithdrawnEpoetin Delta is an ingredient in the EMA-withdrawn product Dynepo.
Levallorphan
go.drugbank.com/drugs/DB00504Approved(From Martindale, The Extra Pharmacopoeia, 30th ed, p683) … An opioid antagonist with properties similar to those of naloxone; in addition it also possesses some agonist properties.
Prednisolone sodium metazoate
go.drugbank.com/drugs/DB05340InvestigationalATL-2502(Colal-Pred) is an old drug (prednisolone metasulphobenzoate, a steroid) with a new delivery system that releases the medication only in the colon. … Colal-Pred is being studied for use in ulcerative colitis.
Polistes fuscatus venom protein
go.drugbank.com/drugs/DB10959ApprovedPolistes fuscatus venom protein is an extract of Polistes fuscatus venom. Polistes fuscatus venom protein is used in allergenic testing.
Polistes metricus venom protein
go.drugbank.com/drugs/DB11029ApprovedPolistes metricus venom protein is an extract of Polistes metricus venom. Polistes metricus venom protein is used in allergenic testing.
Vespula squamosa venom protein
go.drugbank.com/drugs/DB11032ApprovedVespula squamosa venom protein is an extract of Vespula squamosa venom. Vespula squamosa venom protein is used in allergenic testing.
Diacetyl benzoyl lathyrol
go.drugbank.com/drugs/DB11260ApprovedDiacetyl benzoyl lathyrol is an active ingredient in whitening creams. It is also reported to be a skin conditioning agent.
Chamomile
go.drugbank.com/drugs/DB14357ApprovedChamomile is a plant/plant extract used in some OTC (over-the-counter) products. It is not an approved drug.
Eleuthero
go.drugbank.com/drugs/DB14303ApprovedInvestigationalEleuthero is a plant/plant extract used in some OTC (over-the-counter) products. It is not an approved drug.
Synonyms: Et Maxim.) Maxim. Root, Acanthopanacis Senticosi Radix Et Rhizoma Seu CaulisRofecoxib
go.drugbank.com/drugs/DB00533ApprovedWithdrawnRofecoxib is used for the treatment of osteoarthritis, rheumatoid arthritis, acute pain in adults, and primary dysmenorrhea, as well as acute treatment of migraine attacks with or without auras. … On September 30, 2004, Merck voluntarily withdrew rofecoxib from the market because of concerns about increased risk of heart attack and stroke associated with long-term, high-dosage use.